Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 12, 2004, Pages 3143-3146

  Xiang, Min Amy ^a   Chen, Robert H ^a,b   Demarest, Keith T ^a   Gunnet, Joseph ^a   Look, Richard ^a   Hageman, William ^a   Murray, William V ^a   Combs, Donald W ^a   Rybczynski, Philip J ^a   Patel, Mona ^a  

^a Johnson Johnson Pharmaceutical R D   (United States)

^b Ace Chemicals and Pharmaceutical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAZEPINE DERIVATIVE; CONIVAPTAN; LIXIVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN V1 RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR ANTAGONIST;

ARTICLE; DRUG SCREENING; DRUG SYNTHESIS; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; THIN LAYER CHROMATOGRAPHY;

ANIMALS; BENZAZEPINES; CELL LINE; DRUG EVALUATION, PRECLINICAL; HUMANS; RATS; RECEPTORS, VASOPRESSIN;

EID: 2442545257     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.04.016     Document Type: Article

References (20)

1. Laszlo F.A., Laszlo F. Jr. Drug News Perspect. 6:1993;591
2. Michel R.H., Kirk C.J., Billah M.M. Biochem. Soc. Trans. 7:1979;861
3. Jard S. Kidney Int., Supp. 26:1988;38
4. Thibonnier M. Regul. Pep. 38:1992;1
5. Laszlo F.A., Laszlo F. Jr., De Wied D. Pharmacol. Rev. 43:1991;73
6. Mah S.C., Hofbauer K.G. Drugs Fut. 12:1987;1055
7. Paranjape S.B., Thibonnier M. Exp. Opin. Invest. Drugs. 10:2001;825
8. Trybulski E.J. Doherty A.H. Annual Reports in Medicinal Chemistry. Vol. 36:2001;159-168 Academic, San Diego
9. Albright J.D., Chan P.S. Curr. Pharm. Des. 3:1997;615
10. Lixivaptan: Martinez-Castelao A. Curr. Opin. Investig. Drugs. 2:2001;525
11. Albright J.D., Reich M.F., Delos Santos E.G., Dusza J.P., Sum F.-W., Venkatesan A.M., Coupet J., Chan P.S., Ru X., Mazandarani H., Bailey T. J. Med. Chem. 41:1998;2442
12. Albright J.D., Delos Santos E.G., Dusza J.P., Chan P.S., Coupet J., Ru X., Mazandarani H. Bioorg. Med. Chem. Lett. 10:2000;695
13. Conivaptan: Norman P., Leeson P.A., Rabasseda X., Castaner J., Castaner R.M. Drugs Fut. 25:2000;1121
14. Matsushita A., Taniguchi N., Koshio H., Yatsu T., Tanaka A. Chem. Pharm. Bull. 48:2000;21
15. Xiang M.A., Chen R.H., Demarest K.T., Gunnet J., Look R., Hageman W., Murray W.V., Combs D.W., Patel M. Bioorg. Med. Chem. Lett. 14:2004;2987
16. Chen, R. H.; Xiang, M. A. WO 02/02531 A1, 2002
17. Chen, R. H; Xiang, M.; Moore, J. B., Jr.; Beavers, M. P. U.S. Patent 5, 972, 939, 1999
18. 1H NMR, CI-MS/ESI/MS and were homogeneous by TLC)
19. 1a receptors
20. The absolute stereochemistry (R enantiomer) of compounds 7p and 7q was assigned via crystal structure analysis of an intermediate prepared by H. Marlon Zhong and co-workers of the Chemical Development Group, Johnson and Johnson Pharmaceutical Research and Development, L.L.C